Although the direct or indirect regulatory effect of CFTR on ENaC still needs to be confirmed, several groups are pursuing ENaC inhibitors as a therapeutic approach to increase ASL depth, and the available data show that interfering with ENaC activity could potentially be beneficial in CF to rehydrate the ASL [45]. The gene discussed is CFTR; the disease is cystic fibrosis.